BR112022005920A2 - USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 - Google Patents
USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2Info
- Publication number
- BR112022005920A2 BR112022005920A2 BR112022005920A BR112022005920A BR112022005920A2 BR 112022005920 A2 BR112022005920 A2 BR 112022005920A2 BR 112022005920 A BR112022005920 A BR 112022005920A BR 112022005920 A BR112022005920 A BR 112022005920A BR 112022005920 A2 BR112022005920 A2 BR 112022005920A2
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- seq
- acute respiratory
- respiratory syndrome
- immunity against
- Prior art date
Links
- 241000315672 SARS coronavirus Species 0.000 title abstract 3
- 230000036039 immunity Effects 0.000 title abstract 3
- 230000006698 induction Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 241000598171 Human adenovirus sp. Species 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
uso do agente para indução de imunidade específica contra o vírus da síndrome respiratória aguda grave sars-cov-2. a presente invenção refere-se ao campo da biotecnologia, imunologia e virologia. o uso do agente é descrito, o dito agente contendo o componente 1, que é um agente na forma de vetor de expressão baseado no genoma da cepa recombinante de adenovírus humano soro-tipo 26 com sítios e1 e e3 deletados do genoma, e o sítio orf6-ad26 é substituído por orf6-ad5 com cassete de expressão integrado selecionado a partir de seq id no: 1, seq id no: 2, seq id no: 3, e/ou contendo um componente 2, que é um agente na forma de vetor de expressão baseado no genoma da cepa recombinante de adenovírus humano sorotipo 5 com sítios e1 e e3 deletados do genoma com cassete de expressão integrado selecionado a partir de seq id no: 1, seq id no: 2, seq id no: 3 para induzir imunidade específica contra o vírus da síndrome respiratória aguda grave sars-cov-2 em indivíduos acima de 60 anos de idade e/ou portadores de doenças crônicas.use of the agent to induce specific immunity against the severe acute respiratory syndrome virus sars-cov-2. The present invention relates to the field of biotechnology, immunology and virology. the use of the agent is described, said agent containing component 1, which is an agent in the form of an expression vector based on the genome of the recombinant strain of human adenovirus sero-type 26 with sites e1 and e3 deleted from the genome, and the site orf6-ad26 is replaced by orf6-ad5 with integrated expression cassette selected from seq id no: 1, seq id no: 2, seq id no: 3, and/or containing a component 2, which is an agent in the form of expression vector based on the genome of the recombinant strain of human adenovirus serotype 5 with sites e1 and e3 deleted from the genome with integrated expression cassette selected from seq id no: 1, seq id no: 2, seq id no: 3 for induce specific immunity against the severe acute respiratory syndrome virus sars-cov-2 in individuals over 60 years of age and/or with chronic diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021104430A RU2744442C1 (en) | 2021-02-21 | 2021-02-21 | Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions) |
PCT/RU2022/000045 WO2022177465A1 (en) | 2021-02-21 | 2022-02-18 | The use of the agent for inducing immunity to sars-cov-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005920A2 true BR112022005920A2 (en) | 2023-11-07 |
Family
ID=82850909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005920A BR112022005920A2 (en) | 2021-02-21 | 2022-02-18 | USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4294439A1 (en) |
JP (1) | JP2023507543A (en) |
KR (1) | KR20230175091A (en) |
CN (1) | CN115226392A (en) |
BR (1) | BR112022005920A2 (en) |
CA (1) | CA3156448A1 (en) |
IL (1) | IL291803B1 (en) |
MX (1) | MX2022004060A (en) |
ZA (1) | ZA202203564B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2731342C9 (en) * | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments) |
-
2022
- 2022-02-18 CN CN202280000638.8A patent/CN115226392A/en active Pending
- 2022-02-18 EP EP22713845.0A patent/EP4294439A1/en active Pending
- 2022-02-18 KR KR1020227010867A patent/KR20230175091A/en unknown
- 2022-02-18 CA CA3156448A patent/CA3156448A1/en not_active Abandoned
- 2022-02-18 BR BR112022005920A patent/BR112022005920A2/en unknown
- 2022-02-18 JP JP2022520003A patent/JP2023507543A/en active Pending
- 2022-02-18 IL IL291803A patent/IL291803B1/en unknown
- 2022-02-18 MX MX2022004060A patent/MX2022004060A/en unknown
- 2022-03-28 ZA ZA2022/03564A patent/ZA202203564B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230175091A (en) | 2023-12-29 |
MX2022004060A (en) | 2022-09-19 |
IL291803A (en) | 2022-06-01 |
CN115226392A (en) | 2022-10-21 |
ZA202203564B (en) | 2023-11-29 |
JP2023507543A (en) | 2023-02-24 |
CA3156448A1 (en) | 2022-08-21 |
EP4294439A1 (en) | 2023-12-27 |
IL291803B1 (en) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012024934A2 (en) | pharmacologically induced transgene ablation systems | |
BRPI0707543B8 (en) | polypeptide composition and use thereof | |
Oshansky et al. | The human side of influenza | |
BR112013005427A2 (en) | immunogenic composition, vaccine, method for treating or preventing disease, and for preparing the immunogenic composition or vaccine, use of the vaccine, and pharmaceutical composition. | |
Roy et al. | The Delta Plus variant of COVID-19: will it be the worst nightmare in the SARS-CoV-2 pandemic? | |
BR112015030355A8 (en) | use of a protein or an adenylyl cyclase type 6 (ac6) polypeptide incompetent with adenosine cyclic monophosphate (incompetent with camp) or a gene or nucleic acid encoding ac6mut, and, formulation | |
MX2022003069A (en) | Agent for inducing specific immunity against sars-cov-2. | |
BR112022016991A2 (en) | METHODS FOR TREATING A HUMAN SUBJECT SUFFERING FROM CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME OR PNEUMONIA, FOR TREATMENT, PREVENTION, OR REDUCTION OF SEVERITY OR COAGULATION OR THROMBOSIS IN A HUMAN SUBJECT INFECTED WITH SERIOUS ACUTE RESPIRATORY SYNDROME CORONAVIRUS VIRUSES, IMPROVE, PREVENT OR REDUCE THE RISK OF DEVELOPING ONE OR MORE LONG-TERM SEQUELATES RELATED TO CORONAVIRUS | |
Shojaeefar et al. | The possible double‐edged sword effects of vitamin D on COVID‐19: A hypothesis | |
PE20090653A1 (en) | IMMUNOGENIC FORMULATION, BECAUSE IT INCLUDES AN ATTENUATED RECOMBINANT STRAIN OF MYCOBACTERIUM, PREFERENTIALLY THE RECOMBINANT STRAIN BACILO DE CALMETTE AND GUERIN (BCG), WHICH EXPRESSES AT LEAST ONE PROTEIN OR RESPIRATORY IMMUNOGENIC FRAGMENT OF THE VIRUS | |
Liodaki et al. | Epidemiology of pneumonia in a burn care unit: the influence of inhalation trauma on pneumonia and of pneumonia on burn mortality | |
BRPI0516542A (en) | composition of vaccine effective in preventing or ameliorating infection with avian influenza virus; method to prevent or improve the outbreak of infection by avian influenza virus | |
BR112022005920A2 (en) | USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 | |
BR112017013270A2 (en) | "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition." | |
BR112022004778A2 (en) | AGENT FOR SPECIFIC IMMUNITY INDUCTION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 IN LYOPHILIZED FORM (VARIANTS) AND USE | |
ZA202301438B (en) | Aa v5-based vaccine against sars-cov-2 | |
BR112022003581A2 (en) | EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 | |
BR112022005967A2 (en) | USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SARS-COV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS FOR POPULATION REVACCINATION (VARIANTS) | |
Chakraborty et al. | Identification of promising CD8 and CD4 T cell epitopes for peptide vaccine formulation against SARS-CoV-2 | |
BRPI0513118A (en) | recombinant marek virus, vaccine and use of a virus | |
AR124744A1 (en) | AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS) | |
AR124461A1 (en) | AAV5-BASED VACCINE FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARS-CoV-2 AND/OR THE PREVENTION OF SARS-CoV-2-RELATED CORONAVIRUS INFECTION | |
AR124745A1 (en) | AGENT FOR USE IN THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 FOR POPULATION REVACCINATION (VARIANTS) | |
BR112022003611A2 (en) | PHARMACEUTICAL AGENT TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-COV-2 | |
NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella |